The results showed that the combination of EOAI3402143 and trametinib treatment had better tumor growth control than anti-PD-1 treatment (Supplementary Fig. 9c–f), which might provide a rationale for using EOAI3402143 and trametinib combination treatment over anti-PD-1 therapy in cancer patients. This evidence concerns the gene PDCD1 and neoplasm.